Dated: September 26, 2007.

John Howard,

Director, National Institute for Occupational Safety and Health.

[FR Doc. E7–19531 Filed 10–2–07; 8:45 am]

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institute for Occupational Safety and Health; Decision To Evaluate a Petition To Designate a Class of Employees at the Y–12 Facility, Oak Ridge, TN, To Be Included in the Special Exposure Cohort

AGENCY: National Institute for Occupational Safety and Health (NIOSH), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (HHS) gives notice as required by 42 CFR 83.12(e) of a decision to evaluate a petition to designate a class of employees at the Y–12 facility, Oak Ridge, Tennessee, to be included in the Special Exposure Cohort under the Energy Employees Occupational Illness Compensation Program Act of 2000. The initial proposed definition for the class being evaluated, subject to revision as warranted by the evaluation, is as follows:

Facility: Y–12.

Location: Oak Ridge, Tennessee.

Job Titles and/or Job Duties: All workers.

Period of Employment: March 1, 1943 through December 31, 1947.

FOR FURTHER INFORMATION CONTACT: Larry Elliott, Director, Office of Compensation Analysis and Support, National Institute for Occupational Safety and Health (NIOSH), 4676 Columbia Parkway, MS C–46, Cincinnati, OH 45226, Telephone 513–533–6800 (this is not a toll-free number). Information requests can also be submitted by e-mail to *OCAS@CDC.GOV*.

Dated: September 27, 2007.

John Howard,

Director, National Institute for Occupational Safety and Health.

[FR Doc. E7–19525 Filed 10–2–07; 8:45 am]

BILLING CODE 4163–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Statement of Organization, Functions and Delegation of Authority

Notice is hereby given that I have redelegated to the Regional Program Managers, Office of Child Support Enforcement, the following authority vested in me by the Assistant Secretary for Children and Families in the memorandum dated February 16, 2007.

(a) Authority Delegated.

1. The authority to serve as the Approving Official to sign audit determination letters only where resolution does not involve a cost disallowance.

(b) Limitations.

1. This redelegation shall be exercised under financial and administrative requirements applicable to all Administration for Children and Familites authorities.

2. This authority may not be redelegated.

(c) Effective Date.

This redelegation is effective upon the date of signature.

(d) Effect on Existing Delegations.

None.

I hereby affirm and ratify any actions taken by any Regional Program Manager which, in effect, involved the exercise of this authority prior to the effective date of this redelegation.

Dated: August 14, 2007.

Margot Bean,

Deputy Director/Commissioner, Office of Child Support Enforcement.

[FR Doc. 07–4885 Filed 10–2–07; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2007N–0018]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Human Cells, Tissues, and Cellular and Tissue-Based Products: Establishment Registration and Listing; Form Food and Drug Administration 3356; Eligibility Determination for Donors; and Current Good Tissue Practice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Human Cells, Tissues, and Cellular and Tissue-Based Products: Establishment Registration and Listing; Form FDA 3356; Eligibility Determination for Donors; and Current Good Tissue Practice'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of the Chief Information Officer (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4659.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of April 27, 2007 (72 FR 21027), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0543. The approval expires on August 31, 2010. A copy of the supporting statement for this information collection is available on the Internet at *http://www.fda.gov/ohrms/dockets*.

Dated: September 26, 2007.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. E7–19454 Filed 10–2–07; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2006N–0475]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Human Tissue Intended for Transplantation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Human Tissue Intended for Transplantation'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of the Chief Information Officer (HFA–250), Food

and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–4659.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of April 25, 2007 (72 FR 20555), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0302. The approval expires on August 31, 2010. A copy of the supporting statement for this information collection is available on the Internet at *http://www.fda.gov/ohrms/dockets*.

Dated: September 26, 2007.

Jeffrey Shuren,

Assistant Commissioner for Policy.

[FR Doc. E7–19457 Filed 10–2–07; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Nominations for Membership on the Board of Directors of the Reagan-Udall Foundation From Consumer Advocacy Groups, Professional Scientific and Medical Societies, and Industry Trade Organizations

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the opportunity for patient and consumer advocacy groups, professional scientific and medical societies, and industry trade organizations to nominate candidates to serve on the Board of Directors (the Board) of a new non-profit foundation, the Reagan-Udall Foundation for the Food and Drug Administration (the Foundation). The Foundation will be dedicated to modernizing medical, veterinary, food, food ingredient, and cosmetic product development, accelerating innovation, and enhancing product safety.

DATES: Submit written or electronic nominations on or before October 15, 2007.

ADDRESSES: Submit written nominations either by fax to Lisa Rovin or Nancy Stanisic at 301–443–9718 or by e-mail to *Reagan-Udall-Board@FDA.HHS.GOV*.

FOR FURTHER INFORMATION CONTACT:

Lisa Rovin, Office of Policy and Planning (HF–11), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1443; or

Nancy Stanisic, Office of Critical Path Programs (HF–18), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1660.

SUPPLEMENTARY INFORMATION:

I. Background

On September 27, 2007, the President signed into law the Food and Drug Administration Amendments Act of 2007 (FDAAA). The law reauthorizes the Prescription Drug User Fee Act, the Medical Device User Fee Act, the Best Pharmaceuticals for Children Act, and the Pediatric Research Equity Act of 2007, and enacts the Pediatric Medical Device Safety and Improvement Act of 2007 as well as additional requirements and authorities for FDA. Title VI of FDAAA creates the Foundation. The purpose of the Foundation is to ''advance the mission of the Food and Drug Administration to modernize medical, veterinary, food, food ingredient, and cosmetic product development, accelerate innovation, and enhance product safety.''

The duties of the Foundation include the identification of unmet needs in the development, manufacture, and evaluation (including postmarket evaluation) of the safety and effectiveness of FDA-regulated products, and the establishment of scientific and other projects and programs to meet those needs.

II. Criteria for Board Membership

The statute mandates a 14-member Board of Directors, composed of the following:

- Four representatives of the general pharmaceutical, device, food, cosmetic, and biotechnology industries;
- Three representatives of academic research organizations;
- Two representatives of patient or consumer advocacy organizations;
- One representative of health care providers; and
- Four at-large representatives with expertise or experience relevant to the purpose of the Foundation.

The Board must include individuals with expertise in areas including the sciences of developing, manufacturing, and evaluating the safety and effectiveness of devices, including diagnostics, biological products, and drugs, and the safety of food, food ingredients, and cosmetics.

The Foundation's Board will be responsible for governing the organization and ensuring that it succeeds in its mission. To that end, the Board members will oversee the mission and operations of the Foundation, including: Approving programs and monitoring their effectiveness, coordinating Foundation activities with federal research programs, awarding grants, and ensuring financial solvency and raising resources.

The initial Board is to be appointed no later than 30 days after enactment, September 27, 2007, by the ex officio board members designated in the statute: The Commissioner of Food and Drugs, the Director of the National Institutes of Health, the Director of the Centers for Disease Control and Prevention, and the Director of the Agency for Healthcare Research and Quality. Nine Board members are to be appointed from a list of candidates provided by the National Academy of Sciences. Five Board members are to be appointed from lists of candidates provided by ''patient and consumer advocacy groups, professional scientific and medical societies, and industry trade organizations.''

III. Process and Criteria for Nominations

To facilitate nomination of candidates from patient and consumer advocacy groups, professional scientific and medical societies, and industry trade organizations, FDA is publishing this notice and accepting nominations by fax or e-mail submission (see **ADDRESSES**). We welcome nominations from any such organization, and are not limiting the number of nominations each organization may submit. We will accept joint nominations from multiple organizations.

Each nomination should include the following information:

(1) Name, affiliation, and contact information for each nominating organization, and a statement indicating to which of the following categories the nominating organization belongs: Patient and consumer advocacy groups, professional scientific and medical societies, and industry trade organizations.

(2) Name, title, affiliation (if any), resume or curriculum vitae, and contact information for each nominee. In addition, please include no more than one paragraph describing the individual's qualifications in relation to the mission of the Foundation and the statutory criteria for Board membership, described in section II of this document. A nominee may qualify in more than one of the statutory categories for Board membership; please list all categories for which each nominee qualifies.